VCEL

Vericel Corporation (VCEL) | Rumor.io

Vericel

VCEL

Attention (50-day avg)0%

Attention rank (50-day avg)#4,270

Bullish sentiment (50-day avg)92%

Price to earnings ratio83.8

Market capitalization2.1B

Earnings per share0.48

Dividend yield (TTM)—

Revenue (annual)276.3M

Net income (annual)16.5M

Social

What share of all stock conversation is about VCEL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

May 7

Vericel Corporation ($VCEL) reported Q1 2026 earnings, beating estimates with adjusted EPS of $(0.12) and revenue of $68.425M, up 47.83% and 30.09% YoY, respectively.
The company raised its full-year 2026 financial guidance to $326-336M, with MACI revenue expected to grow 30% and Burn Care revenue by 91%.
Vericel's FDA approval of MACI manufacturing is expected to drive revenue growth, with the company holding $211M in cash and receiving a $197M BARDA award for NexoBrid procurement.

Generated by AI

Sentiment

Of the messages about VCEL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	80% -20	74.38% +17.46
Bearish	—	—	20% new	25.62% -17.46

Bullish· Mar 19

Vericel Corporation's NexoBrid approval is anticipated to be a significant catalyst, with the company already recognizing revenue from the product in 2020.
The stock has demonstrated impressive price appreciation, with a 632% increase from its low point, and is still considered to be at the beginning stages of full commercialization.
Vericel Corporation's revenue growth has been steady, with a 14.70% year-over-year increase in the current quarter, and the company has a strong liquidity position with $257 million in cash.

Bearish· Jun 29

The FDA's backlog and travel restrictions are causing a COVID-related issue for Vericel Corporation, potentially leading to delays.
The market's reaction to Vericel's news is an overreaction, as the company has already addressed the issue in a previous earnings call.
Vericel's stock price decline is a result of a partner receiving a Complete Response Letter (CRL), which is a severe setback for the company.

Generated by AI

Topics

Of the messages about VCEL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	—	11.99%
Analysts	—	—	—	6.94%
Earnings	—	—	—	0.95%
Announcements	—	—	—	57.1%
Controversies	—	—	—	0.63%
Macro	—	—	—	22.4%

Earnings· Feb 26

Vericel Corporation ($VCEL) predicts 32-34m Q4 earnings and 92-94m '18, with a 47% YoY increase.
The company achieved record 4th quarter & full-year revenues, gross margins, and full-year positive adjusted EBITDA for the first time in its history.
Vericel's Q4 earnings beat estimates by $0.07 EPS, with revenue also beating expectations, and guidance for 2019 was given as $108-112 million.

Announcements· Jan 10

Vericel Corporation announced preliminary fourth-quarter and full-year 2022 financial results, with revenue guidance of $164-165 million.
The company accelerated its launch timeline for the MACI Arthroscopic Program.
Vericel's shares rose 13% on the news of the preliminary FY22 revenue gain and accelerated MACI launch.

Technical Analysis· Dec 16

$VCEL is expected to be bullish if it holds above $3, with a golden cross line being a strong indicator for professional technicians.
Technical analysis suggests waiting for $VCEL to downtrend further before sniping a long, with a possible bounce on the gap fill and support at $3.20.
The MACD graph indicates $VCEL's potential direction, with the blue line cutting the yellow line suggesting a specific trend, and the stock's momentum expected to play out at the low/mid $2s.

Generated by AI

Community

Of the messages about VCEL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	20%	36.49%
Newcomers	—	—	80%	63.51%

Regulars· May 10

Vericel Corporation reports Q1 EPS of -$0.16, missing consensus by $0.03, but beats on revenue at $41.01M, exceeding estimates by $3.64M.
The company raises its full-year 2023 financial guidance, with no further details provided in the available posts.
Vericel Corporation files SEC Form 10-Q and Form 8-K, reporting its Q1 2023 financial results and raising its full-year 2023 financial guidance.

Newcomers· Jan 15

New to discussing $VCEL, users are optimistic about the company's prospects, with one user mentioning "watch this space".
Users are comparing $VCEL to other companies, such as $MDWD, with one user listing $VCEL as a commentary on $MDWD's prospects.
The focus is on the company's commentary and discussion, rather than specific news or events.

Generated by AI

Vericel has delivered a solid 31.4% share price gain over the past year, which naturally puts a spotlight on whether that move lines up with the cash the business is expected to generate. With the stock last closing at US$39.71, the key issue for you is whether that market value can be reconciled with what its cash flows imply through a Discounted Cash Flow (DCF) lens. The 31.4% one year return has rewarded existing holders, so any fresh money coming in now needs a clear view on what the...

3d agoYahoo Finance

Why the Pentagon Keeps Funding This Small Cap (Nasdaq: MDWD) - MediWound (NASDAQ:MDWD), Vericel (NASDAQ:V

WSW, NY, September 22nd, 2026, FinanceWireOn September 22, MediWound disclosed that the Department of War had added to a program it has been backing since long before most investors had heard of the company. What it

7d agoBenzinga

Vericel (VCEL) Presents At Needham & Co. 20th Annual Growth Conference - Slideshow (NASDAQ:VCEL) 2018-01-19

13d agoSeeking Alpha

Vericel Stock: MACI And Regenerative Knee Cartilage (NASDAQ:VCEL)

Vericel stock outlook: MACI growth, expanded Burlington capacity, BARDA burn-care support, and pipeline catalysts—see why bulls call VCEL a Buy despite premium.

15d agoSeeking Alpha

Wall Street Analysts Are Bullish on Top Healthcare Picks

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

3 Major Earnings Winners You May Have Missed

Detailed price information for International Paper Company (IP-N) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Also Discussed

Investors talking about VCEL also mention

#	Name	Attention
1	MediWound Ltd.MDWD	0%0
2	SINO - Singularity Future Technology Ltd.	——
3	Euroseas Ltd.ESEA	0%0
4	MACK - Merrimack Pharmaceuticals, Inc.	——
5	EVOK - Evoke Pharma, Inc.	——
6	MRNS - Marinus Pharmaceuticals, Inc.	——
7	BioLife Solutions Inc.BLFS	0%0
8	Aurinia Pharmaceuticals IncAUPH	0.01%+0.01
9	Ocular Therapeutix, Inc.OCUL	0.02%-0.04
10	Verastem Inc.VSTM	0%0

Vericel Corporation

Healthcare
Biotechnology

Vericel Corporation is a commercial-stage biopharmaceutical company focused on advanced cell therapies and specialty biologics for sports medicine and severe burn care. Vericel develops, manufactures, and markets products that support the repair of damaged tissue and the restoration of function in patients with serious injuries. Its commercial portfolio includes MACI, a cell therapy used in knee cartilage repair; Epicel, a skin replacement product for severe burns; and NexoBrid, an enzymatic biologic used for eschar removal in burn care. The company serves hospitals, surgeons, and specialized care teams across the United States, with its products positioned within regenerative medicine and acute wound care. Vericel’s business centers on translating cell-based science into practical treatments for complex orthopedic and burn-related conditions.

Website

Location

64 Sidney Street

Cambridge, MA, 02139

United States

Social

What share of all stock conversation is about VCEL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

May 7

Vericel Corporation ($VCEL) reported Q1 2026 earnings, beating estimates with adjusted EPS of $(0.12) and revenue of $68.425M, up 47.83% and 30.09% YoY, respectively.
The company raised its full-year 2026 financial guidance to $326-336M, with MACI revenue expected to grow 30% and Burn Care revenue by 91%.
Vericel's FDA approval of MACI manufacturing is expected to drive revenue growth, with the company holding $211M in cash and receiving a $197M BARDA award for NexoBrid procurement.

Generated by AI

Sentiment

Of the messages about VCEL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	80% -20	74.38% +17.46
Bearish	—	—	20% new	25.62% -17.46

Bullish· Mar 19

Vericel Corporation's NexoBrid approval is anticipated to be a significant catalyst, with the company already recognizing revenue from the product in 2020.
The stock has demonstrated impressive price appreciation, with a 632% increase from its low point, and is still considered to be at the beginning stages of full commercialization.
Vericel Corporation's revenue growth has been steady, with a 14.70% year-over-year increase in the current quarter, and the company has a strong liquidity position with $257 million in cash.

Bearish· Jun 29

The FDA's backlog and travel restrictions are causing a COVID-related issue for Vericel Corporation, potentially leading to delays.
The market's reaction to Vericel's news is an overreaction, as the company has already addressed the issue in a previous earnings call.
Vericel's stock price decline is a result of a partner receiving a Complete Response Letter (CRL), which is a severe setback for the company.

Generated by AI

Topics

Of the messages about VCEL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	—	11.99%
Analysts	—	—	—	6.94%
Earnings	—	—	—	0.95%
Announcements	—	—	—	57.1%
Controversies	—	—	—	0.63%
Macro	—	—	—	22.4%

Earnings· Feb 26

Vericel Corporation ($VCEL) predicts 32-34m Q4 earnings and 92-94m '18, with a 47% YoY increase.
The company achieved record 4th quarter & full-year revenues, gross margins, and full-year positive adjusted EBITDA for the first time in its history.
Vericel's Q4 earnings beat estimates by $0.07 EPS, with revenue also beating expectations, and guidance for 2019 was given as $108-112 million.

Announcements· Jan 10

Vericel Corporation announced preliminary fourth-quarter and full-year 2022 financial results, with revenue guidance of $164-165 million.
The company accelerated its launch timeline for the MACI Arthroscopic Program.
Vericel's shares rose 13% on the news of the preliminary FY22 revenue gain and accelerated MACI launch.

Technical Analysis· Dec 16

$VCEL is expected to be bullish if it holds above $3, with a golden cross line being a strong indicator for professional technicians.
Technical analysis suggests waiting for $VCEL to downtrend further before sniping a long, with a possible bounce on the gap fill and support at $3.20.
The MACD graph indicates $VCEL's potential direction, with the blue line cutting the yellow line suggesting a specific trend, and the stock's momentum expected to play out at the low/mid $2s.

Generated by AI

Community

Of the messages about VCEL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	20%	36.49%
Newcomers	—	—	80%	63.51%

Regulars· May 10

Vericel Corporation reports Q1 EPS of -$0.16, missing consensus by $0.03, but beats on revenue at $41.01M, exceeding estimates by $3.64M.
The company raises its full-year 2023 financial guidance, with no further details provided in the available posts.
Vericel Corporation files SEC Form 10-Q and Form 8-K, reporting its Q1 2023 financial results and raising its full-year 2023 financial guidance.

Newcomers· Jan 15

New to discussing $VCEL, users are optimistic about the company's prospects, with one user mentioning "watch this space".
Users are comparing $VCEL to other companies, such as $MDWD, with one user listing $VCEL as a commentary on $MDWD's prospects.
The focus is on the company's commentary and discussion, rather than specific news or events.

Generated by AI

Vericel

Social

May 7

Bullish· Mar 19

Bearish· Jun 29

Earnings· Feb 26

Announcements· Jan 10

Technical Analysis· Dec 16

Regulars· May 10

Newcomers· Jan 15

Vericel (VCEL) Stock Looks Fully Priced After A 31% Gain

Why the Pentagon Keeps Funding This Small Cap (Nasdaq: MDWD) - MediWound (NASDAQ:MDWD), Vericel (NASDAQ:V

Vericel (VCEL) Presents At Needham & Co. 20th Annual Growth Conference - Slideshow (NASDAQ:VCEL) 2018-01-19

Vericel Stock: MACI And Regenerative Knee Cartilage (NASDAQ:VCEL)

Wall Street Analysts Are Bullish on Top Healthcare Picks

3 Major Earnings Winners You May Have Missed

Also Discussed

Vericel Corporation

Company Information

Location

Vericel (VCEL) Stock Looks Fully Priced After A 31% Gain

Why the Pentagon Keeps Funding This Small Cap (Nasdaq: MDWD) - MediWound (NASDAQ:MDWD), Vericel (NASDAQ:V

Vericel (VCEL) Presents At Needham & Co. 20th Annual Growth Conference - Slideshow (NASDAQ:VCEL) 2018-01-19

Vericel Stock: MACI And Regenerative Knee Cartilage (NASDAQ:VCEL)

Wall Street Analysts Are Bullish on Top Healthcare Picks

3 Major Earnings Winners You May Have Missed

Also Discussed

Social

May 7

Bullish· Mar 19

Bearish· Jun 29

Earnings· Feb 26

Announcements· Jan 10

Technical Analysis· Dec 16

Regulars· May 10

Newcomers· Jan 15